<DOC>
	<DOCNO>NCT01029873</DOCNO>
	<brief_summary>This Phase Ib/II , open-label , multi-center , competitive enrollment dose-escalation study ALT-801 combine cisplatin . The purpose study evaluate safety , determine Maximum-Tolerated Dose ( MTD ) , characterize pharmacokinetic profile ALT-801 give cisplatin patient chemotherapy naïve metastatic melanoma consider surgically incurable . The anti-tumor response ALT-801 cisplatin also assess trial .</brief_summary>
	<brief_title>QUILT-2.008 : Study ALT-801 With Cisplatin Patients With Metastatic Melanoma</brief_title>
	<detailed_description>Most current cancer treatment strategy involve use chemotherapeutic biological drug exhibit variable efficacy considerable toxicity . The limitation often result adverse side effect therapeutic drug normal tissue . One approach control effect target therapy tumor site . Of identified tumor antigen , human p53 tumor suppressor protein overexpressed wide range human malignancy . p53 intracellular tumor suppressor protein act arrest proliferation cell . When mutate , lose ability suppress abnormal proliferation exhibit longer half-life wild-type protein , allow accumulation tumor . In addition , p53 overexpression correlate tumor transformation aggression associate low overall survival rate resistance chemotherapeutic intervention cancer patient . Therefore , p53 appear marker considerable number human malignancy represent good target immunotherapeutics . However , p53 use target antibody display independently cell surface . Instead , p53 protein process intracellularly peptide fragment display cell surface context MHC . These peptide/MHC complex recognize T-cells via T-cell receptor ( TCRs ) . Recently confirm p53 peptide fragment significantly elevate wide range human tumor tissue , particularly melanoma , renal , lung , breast , colorectal , osteosarcoma cancer . As result , feasibility use soluble TCRs target therapy tumor cell overexpress p53 investigate . Interleukin-2 ( IL-2 ) well-characterized growth factor immune effector cell play critical role tumor control rejection . As result , recombinant human IL-2 ( e.g. , Proleukin® , Chiron Novartis ) approve treatment metastatic melanoma renal cell carcinoma . IL-2 treatment provide significant benefit subset patient maintain durable response ten year post-treatment . However , major drawback IL-2 therapy limit half-life severe systemic toxicity . Hence , use high dose IL-2 limit specialized program experience personnel , generally offer patient responsive excellent organ function . The low dose IL-2 treatment , less toxic convenient , produce low response rate appear less effective treat metastatic tumor . Thus , critical need innovative strategy enhance effect IL-2 reduce toxicity without compromise clinical benefit . Targeted approach concentrate therapeutic cytokine , IL-2 , tumor site express p53 could provide considerable advantage current treatment . The study drug , ALT-801 , biologic compound compose interleukin-2 ( IL-2 ) genetically fuse humanize soluble T-cell receptor direct p53-derived peptide express tumor cell . This study evaluate whether direct IL-2 activity use ALT-801 patient 's tumor sit overexpress p53 result clinical benefit ALT-801 treatment give cisplatin . Platinum-based analogue include cisplatin , alone combination chemotherapy , show active patient metastatic melanoma . Additionally , know cisplatin , alkylating agent know inhibit DNA synthesis divide cell , trigger increase intracellular level p53 . The synergistic effect cisplatin ALT-801 treatment may induce cisplatin-mediated increase p53 peptide display tumor subsequently enhance tumor target ALT-801 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>ENTRY CRITERIA : DISEASE CHARACTERISTICS : Locally advance metastatic melanoma Measurable Histologically cytologically confirm Surgically incurable HLAA2 positive tumor present HLAA2.1/p53aa264272 complex PRIOR/CONCURRENT THERAPY : If prior Proleukin treatment , must clinical benefit No prior systemic cytotoxic chemotherapy melanoma No concurrent radiotherapy , chemotherapy , immunotherapy More 4 week since prior major radiotherapy More 8 week since prior CTLA4 antagonist immunotherapy Not receive investigational agent PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month Performance status ECOG 0 1 Bone marrow reserve Absolute neutrophil count ( AGC/ANC ) ≥ 1,500/uL Platelets ≥100,000/uL Hemoglobin ≥ 10g/dL Renal function Serum creatinine ≤ 1.5 mg/dL Hepatic function Total bilirubin ≤ 1.5 X ULN AST ≤ 2.5 X ULN Alkaline phosphatase ≤ 2.5 X ULN PT INR ≤ 1.5 X ULN aPTT ≤ 1.5 X ULN Cardiovascular May safely taper antihypertensive currently antihypertensives New York Heart Association classification I II No congestive heart failure &lt; 6 month No unstable angina pectoris &lt; 6 month No myocardial infarction &lt; 6 month No history ventricular arrhythmia Normal cardiac stress test require following present : Age ≥ 50 History abnormal EKG Symptoms cardiac ischemia arrhythmia Pulmonary Normal pulmonary function test ( FEV1 ≥ 70 % predict value ) follow present : Prolonged history cigarette smoking Symptoms respiratory dysfunction Other No know autoimmune disease No known HIV positive No psychiatric illness/social situation would limit study compliance No history evidence CNS disease No active systemic infection require parental antibiotic therapy No systemic steroid therapy require No prior organ allograft allogeneic transplantation Not receive chronic medication asthma Not pregnant nursing Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>target</keyword>
	<keyword>metastatic</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>antitumor</keyword>
	<keyword>melanoma</keyword>
	<keyword>TCR</keyword>
	<keyword>T-cell receptor</keyword>
	<keyword>p53</keyword>
	<keyword>p53 gene</keyword>
	<keyword>p53 tumor suppressor protein</keyword>
</DOC>